Literature DB >> 6791228

Effect of chronic amphetamine administration on central dopaminergic mechanisms in the vervet.

F Owen, H F Baker, R M Ridley, A J Cross, T J Crow.   

Abstract

A biochemical study of central dopaminergic mechanisms was carried out in brain tissue from vervet monkeys who had been subjected to chronic amphetamine administration. The brain concentrations of dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were markedly reduced. Significant reductions were also observed in the activities of dopa-decarboxylase (DDC) and tyrosine hydroxylase (TH). A kinetic study of TH revealed a 60% reduction in maximum reaction velocity, consistent with destruction of DA neurones. However, homovanillic acid (HVA) concentrations were only moderately reduced, suggesting a nearly normal production of DA. Hence despite the large depletions in DA concentrations, high affinity binding of 3H-spiperone binding to striatal DA receptors was no different from controls. The results are discussed in relation to the amphetamine psychosis in humans.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6791228     DOI: 10.1007/BF00427096

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Increased HVA levels in primate ventricular CSF following amphetamine administration.

Authors:  H F Baker; R M Ridley
Journal:  Brain Res       Date:  1979-05-05       Impact factor: 3.252

2.  Multiple daily amphetamine administration: behavioral and neurochemical alterations.

Authors:  D S Segal; S B Weinberger; J Cahill; S J McCunney
Journal:  Science       Date:  1980-02-22       Impact factor: 47.728

3.  Adaptation of the liquid cation exchange method for the assay of 3,4-dihydroxy-L-phenylalanine and 5-hydroxy-L-tryptophan decarboxylases in rat brain.

Authors:  A Vaccari
Journal:  Brain Res       Date:  1976-09-10       Impact factor: 3.252

4.  Dextroamphetamine. Evaluation of psychomimetic properties in man.

Authors:  J D Griffith; J Cavanaugh; J Held; J A Oates
Journal:  Arch Gen Psychiatry       Date:  1972-02

5.  Further studies on the increase of striatal homovanillic acid induced by amphetamine and fenfluramine.

Authors:  A Jori; D Bernardi
Journal:  Eur J Pharmacol       Date:  1972-08       Impact factor: 4.432

6.  Catecholamines in fetal and newborn rat brain.

Authors:  J T Coyle; D Henry
Journal:  J Neurochem       Date:  1973-07       Impact factor: 5.372

7.  Biochemical differentiation of amphetamine vs methylphenidate and nomifensine in rats.

Authors:  C Braestrup
Journal:  J Pharm Pharmacol       Date:  1977-08       Impact factor: 3.765

8.  D-amphetamine-induced release of "newly synthesized" and "stored" dopamine from the caudate nucleus in vivo.

Authors:  C C Chiueh; K E Moore
Journal:  J Pharmacol Exp Ther       Date:  1975-03       Impact factor: 4.030

9.  Increased dopamine-receptor sensitivity in schizophrenia.

Authors:  F Owen; A J Cross; T J Crow; A Longden; M Poulter; G J Riley
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

10.  Chronic amphetamine administration to cats: behavioral and neurochemical evidence for decreased central serotonergic function.

Authors:  M E Trulson; B L Jacobs
Journal:  J Pharmacol Exp Ther       Date:  1979-11       Impact factor: 4.030

View more
  3 in total

Review 1.  Behavioural tolerance to amphetamine and other psychostimulants: the case for considering behavioural mechanisms.

Authors:  C Demellweek; A J Goudie
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

2.  Behavioural and biochemical effects of chronic amphetamine treatment in the vervet monkey.

Authors:  R M Ridley; H F Baker; F Owen; A J Cross; T J Crow
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

3.  Stereotyped responding on a two-choice guessing task by marmosets and humans treated with amphetamine.

Authors:  R M Ridley; H F Baker; C D Frith; J Dowdy; T J Crow
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.